We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as important updates in the latest NCCN guidelines.
1. What do you consider the most important unmet needs in the treatment of multiple myeloma? (0:11)
2. What are the most important emerging molecular targets in the treatment of multiple myeloma? (1:14)
3. What new treatment approaches do you expect to emerge in coming years? (3:51)
4. What therapies have become available for patients with relapsed/refractory disease? (4:32)
5. What are the most important updates and changes in the latest NCCN Guidelines for multiple myeloma? (5:33)
Speaker disclosures: Shaji Kumar has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2020 – Highlights from ASH 2020
It was a pleasure to speak with our Editor-in-Chief, Shaji Kumar (Mayo Clinic, Rochester, MN, USA) to discuss the use of MEDI2228 (Clinical Trial Identifier: NCT03489525) and anti-BCMA CAR-T cells (Clinical Trial Identifier: NCT03915184) in the treatment of patients with relapsed/refractory multiple myeloma and to find out his personal highlights from this year’s congress. The […]
Meletios-Athanasios Dimopoulos, ASH 2020 – Results from the Apollo Trial
We caught up with Meletios-Athanasios Dimopoulos (National and Kapodistrian University of Athens School of Medicine, Athens, Greece) to discuss his ASH 2020 presentation on the use of daratumumab in the treatment of relapsed/refractory multiple myeloma (Clinical Trial Identification: NCT03180736). The abstract ‘412 Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) […]
Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma
We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma. Questions 1. What is the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!